Seven additional Phase 3 readouts expected through 2026: TRIUMPH-1 (obesity), TRIUMPH-2 (obesity + diabetes), TRIUMPH-3 (obesity + cardiovascular risk), SELECT-M (MASH), SLEEP (OSA), BACK PAIN, and a cardiovascular/renal outcomes readout
When fat loss outpaces the skin's ability to contract and remodel, laxity results
Hypoglycaemia risk is generally low with GLP-1 agonists alone but may be elevated when combined with insulin or sulfonylureas, particularly in patients with poor nutritional status or irregular eating patterns
GLP-1 weight loss uses a class of medications that mimic GLP-1, a natural gut hormone that helps regulate appetite, blood sugar, and digestion
Popular weight loss drugs remain out of reach for many who need them
Gradual, Steady Progress Weight loss with GLP-1 medications tends to be gradual and sustained when combined with healthy lifestyle habits